View printer-friendly version

ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to name its humanitarian organisation partner as Doctors Without Borders/Médecins San Frontières (MSF), who are moving towards starting a clinical study of ResAppDx in a lower income rural context setting.

According to the World Health Organisation, pneumonia kills more than 950,000 children under five every year. Many such deaths are caused by delays in diagnosis due to the lack of high-quality medical care in these regions.

MSF is an international, independent, medical humanitarian organisation that delivers emergency aid to people affected by armed conflict, epidemics, healthcare exclusion and natural disasters. MSF has expressed an interest in ResAppDx as it recognises its potential, and both parties are willing to collaborate to ensure that those children who will benefit most from this technology are not left behind. MSF has been providing input into ensuring its suitability in humanitarian settings and lower middle income countries.

“We are very pleased with the collaboration to date and we have used the feedback obtained to refine ResAppDx even further for the difficult environments in which MSF operates,” said Tony Keating, CEO and Managing Director of ResApp. “We are looking forward to evaluating the clinical performance of ResAppDx in some of the most challenging conditions that doctors encounter.”

About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a digital health company developing smartphone applications for the diagnosis and management of respiratory disease. The technology is based on machine learning algorithms that use sound to diagnose and measure the severity of respiratory conditions without the need for additional hardware. The algorithms were initially developed by The University of Queensland with funding from the Bill and Melinda Gates Foundation. ResApp has both adult and paediatric clinical studies underway with preliminary results demonstrating accurate diagnosis of pneumonia, asthma/viral wheeze, bronchiolitis, croup and upper respiratory tract infections in children as well as chronic obstructive pulmonary disease, asthma and pneumonia in adults. Markets for ResApp’s technology include telehealth use through partnerships with telehealth service providers, emergency department and regular clinic use by healthcare providers, at-home use by consumers and working with global aid and humanitarian organisations to deliver tools for the developing world.

For more information on ResApp, visit www.resapphealth.com.au.

CONTACT
Dr Tony Keating
CEO and Managing Director
+61 430 180 659
tony@resapphealth.com.au

SHAREHOLDER & MEDIA CONTACT
Brian Leedman
Executive Director and VP, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au
ResApp Logo White

ResApp Health Limited
ABN 51 094 468 318
Headquarters: Level 8, 127 Creek St, Brisbane, QLD 4000
Registered Office: Level 24, 44 St Georges Tce, Perth, WA 6000

© 2017 ResApp Health Limited. All Rights Reserved.

CONTACT US

+61 8 6211 5099
+61 8 9218 8875
General Information
Clinical Studies
Investor Relations

      

LEGAL

Terms of Use
Privacy Policy

ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States.

In the United States, ResAppDx is an investigational device and is not available for sale.